Intellia Therapeutics Inc share price logo

Intellia Therapeutics Inc Share Price

NASDAQ: NTLA

Small Cap

$14.77

+0.51

(+3.58%)

as on

Intellia Therapeutics Inc Stock Performance

as on April 15, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $14.35
    $15.15
    downward going graph

    2.84%

    Downside

    2.57%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $6.73
    $28.25
    downward going graph

    54.43%

    Downside

    91.27%

    Upside

    downward going graph

Intellia Therapeutics Inc share price movements today

Previous Close
$14.26
Open
$14.49
Volume
3.2M
Day's Low - High
$14.35 - $15.15
52 Week Low - High
$6.73 - $28.25

Intellia Therapeutics Inc Historical Returns

1 Month Return
+ 11.76 %
3 Month Return
+ 18.64 %
1 Year Return
+ 90.13 %
3 Year Return
-62.63 %
5 Year Return
-81.32 %

Intellia Therapeutics Inc Stock Fundamentals & Key Indicators

Check Intellia Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.6B

EPS (TTM)

-3.5558

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

-0.0969

EBITDA

-431.2M

Revenue (TTM)

67.7M

Profit Margin

0.00%

Return On Equity TTM

-53.48%

Intellia Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Intellia Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Intellia Therapeutics Inc image
Intellia Therapeutics Inc
BUY$1.6B-81.32%NA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$42.7B140.76%138.848.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$111.0B102.67%28.532.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$35.6BNA124.865.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.2B55.14%18.0531.41%

Stock Returns calculator for Intellia Therapeutics Inc Stock including INR - Dollar returns

The Intellia Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Intellia Therapeutics Inc investment value today

Current value as on today

₹2,13,030

Returns

₹1,13,030

(+113.03%)

Returns from Intellia Therapeutics Inc Stock

₹96,933 (+96.93%)

Dollar Impact

₹16,097 (+16.1%)

Analyst Recommendation on Intellia Therapeutics Inc Stock

Based on 34 analysts

BUY

79.41%

Buy

20.59%

Hold

0.00%

Sell

Based on 34 analysts, 79.41% of analysts recommend a 'BUY' rating for Intellia Therapeutics Inc. Average target price of $25.29

Intellia Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Intellia Therapeutics Inc.

What analysts predicted

41.6%UPSIDE

Target Price

$25.29

Current Price

$14.77

Analyzed by

34 Analysts

Target

$25.29

Intellia Therapeutics Inc target price $25.29, a slight upside of 41.6% compared to current price of $14.77. According to 34 analysts rating.

Intellia Therapeutics Inc Stock’s Investor Sentiment and Interest

Investment in Intellia Therapeutics Inc Shares on INDmoney has dropped by -12.03% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-12.03% versus previous 30 day period

Search interest for Intellia Therapeutics Inc Stock has decreased by -32% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-32% versus previous 30 day period

Intellia Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
11
-1
28
6
9
12
16
14
13
23
Gross Profit
9
-4
26
4
9
12
16
14
-65
17
Operating Income
-131
-139
-114
-139
-144
-136
-120
-109
-111
-98
EBITDA
-128
-137
-111
-136
-142
-133
-118
-107
-96
-95
Interest Expense
-
8
-
-
-
-
-
-
-
-
Depreciation
2
2
2
2
2
2
2
2
4
6
Income Before Tax
-122
-132
-107
-146
-135
-128
-114
-101
-101
-95
Income Tax Expense
-15
40
2
-
-
-
-
-
-
-
Net Income
-122
-132
-107
-146
-135
-128
-114
-101
-101
-95
Net Profit Margin
-1019.21%
6894.16%
-371.30%
-2112.62%
-1489.54%
-1001.23%
-687.61%
-710.81%
-735.19%
-416.15%

Intellia Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
16
26
30
43
57
33
52
36
57
67
Gross Profit
16
26
30
-65
57
33
44
27
47
51
Operating Income
-32
-69
-90
-106
-136
-267
-458
-515
-534
-440
EBITDA
-31
-66
-86
-100
-130
-260
-450
-506
-523
-396
Interest Expense
-
-
-
-
2
6
8
-
-
-
Depreciation
-
2
4
5
6
6
7
8
10
15
Income Before Tax
-31
-67
-85
-99
-134
-267
-474
-481
-519
-412
Income Tax Expense
-1
-2
5
-6
-8
-8
16
-49
-
-
Net Income
-31
-67
-85
-99
-125
-259
-474
-481
-519
-412
Net Profit Margin
-191.97%
-258.62%
-280.42%
-230.92%
-216.52%
-785.76%
-909.78%
-1326.51%
-896.77%
-609.85%

Intellia Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-132
-107
-146
-135
-128
-114
-101
-101
-202
Operating Cash Flow
-93
-120
-58
-84
-85
-148
-99
-76
-69
Investing Cash Flow
45
5
-24
-7
151
94
106
0
27
Financing Cash Flow
106
59
41
82
2
-
14
114
1
Change in Cash
59
-54
-41
-10
68
-54
21
37
-37

Intellia Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-67
-85
-99
-134
-267
-474
-481
-519
-519
Operating Cash Flow
-65
-61
-103
-49
-225
-333
-394
-348
-348
Investing Cash Flow
-10
-260
25
-214
-550
160
-31
125
125
Financing Cash Flow
142
40
76
371
736
582
130
185
185
Change in Cash
67
-281
-1
107
-39
409
-295
-37
-37

Global Institutional Holdings in Intellia Therapeutics Inc

Funds
Holdings
The Goldman Sachs Group Inc
3.62%
ARK Investment Management LLC
12.03%
Geode Capital Management, LLC
2.19%
Morgan Stanley - Brokerage Accounts
5.1%
Amova Asset Management Americas, Inc
1.99%
See all

Intellia Therapeutics Inc News & Key Events

    Insights on Intellia Therapeutics Inc

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 3 months, NTLA stock has moved up by 18.6%

    • imgPOSITIVE IMPACT

      Best in 1 Year

      img

      In the last 1 year, NTLA has outperformed top 5 stocks with highest market-cap in its industry

    • imgPOSITIVE IMPACT

      Profit Spike

      img

      Netprofit is up for the last 2 quarters, -101.32M → -95.78M (in $), with an average increase of 5.8% per quarter

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 2 quarters, 13.78M → 23.01M (in $), with an average increase of 40.1% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 63.3% return, outperforming this stock by 125.9%

    About Intellia Therapeutics Inc

    Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
    OrganisationIntellia Therapeutics Inc
    Headquarters40 Erie Street, Cambridge, MA, United States, 02139
    IndustryBiotechnology
    CEODr. John M. Leonard M.D.
    E-voting on sharesClick here to vote

    Key Management of Intellia Therapeutics Inc

    Name

    Title

    Dr. John M. Leonard M.D.

    President, CEO & Director

    Mr. Michael P. Dube

    VP & Chief Accounting Officer

    Dr. David Lebwohl M.D.

    Executive VP & Chief Medical Officer

    Dr. Rachel E. Haurwitz Ph.D.

    Co-Founder

    Dr. Derrick J. Rossi Ph.D.

    Founder & Member of Scientific Advisor Board

    Dr. Rodolphe Barrangou M.B.A., Ph.D.

    Founder & Member of Scientific Advisor Board

    Prof. Luciano Marraffini Ph.D.

    Founder & Member of Scientific Advisor Board

    Mr. Edward J. Dulac III

    Executive VP, CFO & Treasurer

    Mr. James E. Basta Esq., J.D.

    Executive VP, General Counsel & Corporate Secretary

    Dr. Jennifer A. Doudna Ph.D.

    Founder & Member of Scientific Advisor Board

    FAQs

    What is Intellia Therapeutics Inc share price today?

    Intellia Therapeutics Inc share price today is $14.77 as on at the close of the market. Intellia Therapeutics Inc share today touched a day high of $15.15 and a low of $14.35.

    What is the 52 week high and 52 week low for Intellia Therapeutics Inc share?

    Intellia Therapeutics Inc share touched a 52 week high of $28.25 on and a 52 week low of $6.73 on . Intellia Therapeutics Inc stock price today i.e. is closed at $14.77,which is 47.72% down from its 52 week high and 119.47% up from its 52 week low.

    What is Intellia Therapeutics Inc's market capitalisation today?

    Intellia Therapeutics Inc market capitalisation is $0.00T as on .

    How to invest in Intellia Therapeutics Inc Stock (NTLA) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Intellia Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Intellia Therapeutics Inc Shares that will get you 0.1016 shares as per Intellia Therapeutics Inc share price of $14.77 per share as on April 15, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Intellia Therapeutics Inc Stock (NTLA) from India?

    Indian investors can start investing in Intellia Therapeutics Inc (NTLA) shares with as little as ₹93.082 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹930.82 in Intellia Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Intellia Therapeutics Inc share’s latest price of $14.77 as on April 15, 2026 at 1:29 am IST, you will get 0.6770 shares of Intellia Therapeutics Inc. Learn more about fractional shares .

    What are the returns that Intellia Therapeutics Inc has given to Indian investors in the last 5 years?

    Intellia Therapeutics Inc stock has given -81.32% share price returns and 24.21% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?